Getason

Quick links to important sections

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Getason

Quick Facts

Property Description
Active ingredient Betamethasone Dipropionate
Form Topical preparations (cream, ointment, lotion)
Pharmacological class Glucocorticoid / Corticosteroid
General purpose Anti-inflammatory and anti-itching (antipruritic)
Origin Synthetic

What is Getason and What Type of Drug Is It?

Getason is a specialized, prescription-only topical medication formally classified as a glucocorticoid or corticosteroid. It is engineered for application directly to the skin to manage and relieve symptoms related to inflammation. The drug entity is a synthetic adrenocorticosteroid analogue, which is clinically recognized for its powerful local effect on skin inflammation. This high-potency classification distinguishes it from milder, lower-strength corticosteroids, making it typically reserved for conditions that require a more intensive therapeutic intervention.

Composition and Physical Form of Getason

The therapeutic action of Getason is delivered solely by the single active ingredient, Betamethasone Dipropionate, which dictates the drug's properties. As a single-active ingredient product (monotherapy), the preparation is commonly manufactured in various topical preparations, such as a cream, an emollient ointment, or a lotion. The inclusion of the Dipropionate ester in the chemical structure is a key feature, as it enhances the compound's absorption and retention within the outer skin layers. This chemical modification is what ensures efficient delivery of the active substance to the site of inflammation.

General Purpose and Action of This Corticosteroid

The essential purpose of Getason is to act as a powerful anti-inflammatory agent and antipruritic (anti-itching) compound. It achieves this general benefit by working locally to modulate and quiet excessive immune and inflammatory responses occurring at the application site. This mechanism allows the medication to stabilize affected tissue and provide significant symptomatic relief from severe and persistent itching.

Regulatory References

  1. FDA DailyMed

What side effects are possible with Getason?

Possible side effects and safety information

The safety profile for Getason (Betamethasone Dipropionate) is based on adverse reactions that are officially documented in regulatory labeling. The medicine's risk profile is structured into local skin effects, which are the most frequently reported, and systemic effects, which are associated with absorption through the skin.

Adverse Reactions Classification

Adverse reactions are classified by the organ system affected, known as System-Organ Classes (SOCs), and by frequency. The most common documented reactions are localized to the skin, including burning, itching, irritation, and dryness. Other reported dermatological effects include folliculitis, hypertrichosis, acneiform eruptions, and hypopigmentation. Systemic effects resulting from percutaneous absorption may include endocrine, metabolic, and ophthalmic disorders.

Serious Safety Considerations

Due to its high potency, systemic absorption may lead to serious adverse reactions, particularly with extensive or prolonged use. These include the potential for Hypothalamic-Pituitary-Adrenal (HPA) axis suppression and the manifestations of Cushing's syndrome. Ophthalmic risks, such as an increased incidence of cataracts and glaucoma, are also documented safety concerns. The risk for these serious effects is greater when the medication is applied over large surface areas, used under occlusive dressings, or for long durations.

Population-Specific Safety

Official labeling emphasizes specific safety considerations for pediatric patients, who demonstrate a greater susceptibility to systemic toxicity due to their higher skin surface area-to-body mass ratio. Rare systemic effects reported in this population include linear growth retardation and intracranial hypertension. Cautionary statements also apply to use during pregnancy and lactation, reflecting the need to minimize systemic exposure.

Overdose and Emergency Response

Overdose with Getason (Betamethasone Dipropionate topical) is officially documented as systemic overexposure resulting from prolonged or excessive use or application over extensive body surface areas.

Documented Overdose Manifestations

The most significant manifestation of overexposure is the potential for Hypothalamic-Pituitary-Adrenal (HPA) axis suppression.

Feature Official Regulatory Information
Documented Manifestations: Manifestations of Hypercortisolism (Cushing's syndrome), Hyperglycemia, and Glucosuria (sugar in the urine).
Serious Outcomes: Glucocorticosteroid insufficiency upon abrupt withdrawal following chronic systemic overexposure.
Pediatric Notes: Pediatric patients are at a greater risk of systemic toxicity; specific signs include linear growth retardation and delayed weight gain.

Required Emergency Actions

If overdose is suspected or if symptoms of systemic overexposure appear, individuals must contact a healthcare professional, hospital emergency department, or regional poison control centre immediately.

No specific antidote is documented for topical corticosteroid overexposure. Management involves providing appropriate symptomatic treatment and correcting any electrolyte imbalance as needed. If HPA axis suppression is noted, the official procedure mandates that the drug must be gradually withdrawn by either reducing the frequency of application or substituting a less potent agent. Abrupt withdrawal is to be avoided due to the risk of glucocorticosteroid insufficiency.

Therapeutic Uses of Getason

What Getason Treats: Main Uses and Benefits

The therapeutic use of Getason (Betamethasone Dipropionate) is centered on the relief of inflammatory and pruritic manifestations of a category of skin diseases known as corticosteroid-responsive dermatoses. The high potency of the medication means it is generally reserved for situations that require additional symptomatic support and focused management of distressing manifestations.

It is commonly used across conditions characterized by periods of heightened symptoms, specifically addressing aggressive forms of plaque psoriasis, severe eczema (dermatitis), Lichen Planus, and other chronic inflammatory disorders. It is relevant when symptoms are deemed resistant or have not achieved adequate control with less potent topical agents.

The medication is applied to help address symptom clusters that may become intense or disruptive, such as severe, persistent pruritus (itching) and the physical signs of inflammation like pronounced redness and swelling. It is relevant for easing these heightened symptoms, which supports improved day-to-day comfort.

“It is commonly used to help with the distressing manifestations of inflammation.”

This medication also assists with managing symptoms related to a rough or hardened skin surface, such as scaling, crusting, and the localized thickening known as lichenification. This provides support that helps ease the overall symptom burden and assists with maintaining functional stability when symptoms are more noticeable.


Quick Fact: Symptomatic Focus

Therapeutic Focus Indication Context Symptom Relief
Therapeutic Scope Resistant, chronic inflammatory skin conditions Eases distressing itching and inflammation

Regulatory References

  1. FDA prescribing information via DailyMed

Eligibility and Restrictions for Use

Getason (Betamethasone Dipropionate) eligibility is strictly determined by official regulatory criteria regarding age, underlying health conditions, and patient hypersensitivity. The medicine is contraindicated for any patient with a known allergy to the active ingredient, to other corticosteroids, or to any component of the preparation.

Eligibility and Restriction Status

Population / Condition Regulatory Status Restriction Context
Approved Age Established ge 13 years Use is not recommended for children younger than 13 years due to a higher risk of systemic toxicity and HPA axis suppression [NIH DailyMed 2.1].
Local Conditions Not Recommended Includes Rosacea, Perioral Dermatitis, and untreated skin infections [HPRA 1.9].
Systemic Conditions Use with Caution Liver failure, Glaucoma, and Diabetes [NIH DailyMed 2.3]; these conditions increase the risk of systemic absorption or potential for exacerbation.
Pregnancy/Lactation Conditional Use Use only if the potential benefit justifies the risk; avoid prolonged or extensive application [NIH DailyMed 2.5].

Use is not intended for application on broken or atrophic skin, or in sensitive areas like the face, unless specifically advised and monitored. The restrictions define who can use the medicine and under what labeled circumstances.

What should I know about interactions with other medicines?

The official regulatory interaction profile for Getason (Betamethasone Dipropionate) is primarily defined by the risk of additive systemic exposure rather than specific metabolic drug-drug enzyme interactions.

Interaction Scope

Category Official Regulatory Documentation Statement
Medicinal product categories with documented interactions Corticosteroid-containing products (topical or systemic)
Mechanistic basis of interactions (only if stated in label) Additive Pharmacodynamic Effect: Increased total systemic glucocorticoid exposure.
Population-specific interaction notes (if applicable) Pediatric Patients: Higher documented susceptibility to systemic exposure effects.
Hepatic Impairment: Documented increased risk of enhanced effects due to decreased metabolism.

Interaction-Related Constraints

Official regulatory documents specify conditions that enhance the drug's systemic exposure, which can modify the interaction context.

  • Exposure Modification: The use of occlusive dressings, bandages, or tight-fitting diapers is officially restricted, as this condition significantly enhances the percutaneous absorption of Betamethasone Dipropionate.
  • Procedural Constraint: Application over large body surface areas or for prolonged duration are documented factors that increase the risk of systemic exposure.

The co-administration with other corticosteroid-containing products can result in an additive increase in the total systemic glucocorticoid load, which is classified as a clinically significant caution in official documents. This profile emphasizes conditions that augment systemic exposure and the resulting class effect.

Mechanism of Action

The mechanism of action for Getason (Betamethasone Dipropionate), a glucocorticoid, centers on its role as an agonist for the intracellular Glucocorticoid Receptor ( GR). This interaction dictates profound modulation of inflammatory gene expression.

Upon activation, the Betamethasone- GR complex enters the cell nucleus to perform two genomic functions: transrepression and transactivation. Transrepression blocks the activity of pro-inflammatory transcription factors, such as NF-kappa B. Concurrently, transactivation upregulates the synthesis of anti-inflammatory proteins, notably Annexin A1.

Annexin A1 acts as a functional inhibitor of the enzyme Phospholipase A2 ( PLA2). By restricting PLA2's release of arachidonic acid, the mechanism suppresses the synthesis of subsequent lipid mediators, including prostaglandins and leukotrienes.

This molecular cascade leads to local physiological modulation, characterized by vasoconstriction and decreased capillary permeability, physically restricting blood flow and fluid leakage into the tissue. The combined reduction in inflammatory mediators and the alteration of sensory nerve signaling restrict peripheral pathway activity.

Dosage and Administration Information

How to Use Getason (Betamethasone Dipropionate Topical)

The use of Getason is strictly confined to topical administration, intended for external application directly onto the skin. The preparation is available as a cream, ointment, or lotion, and it should be applied as a thin film gently rubbed into the affected area, typically once or twice daily. To adhere to guidelines and prevent excessive absorption, the total amount of the preparation applied must not exceed 50 g per week.

Therapy is defined by a short course and is intended only for the required period until adequate control of the skin condition is achieved. For the high-potency augmented formulations, treatment is strictly limited to a maximum of 2 consecutive weeks. Should the condition show no clinical improvement after this period, the diagnosis and treatment plan require reassessment.

The official administration guidelines include critical procedural and site constraints. The preparation must not be used with occlusive dressings (bandages or wraps) unless explicitly directed by a healthcare professional. Application must be carefully avoided on sensitive body areas, including the face, groin, and armpits, as well as any skin areas already showing atrophy. Proper use requires the user to wash hands thoroughly after the application is complete. Furthermore, the high-potency formulations are not recommended for pediatric patients 12 years of age and younger. If used in children or on the face, the treatment course is strictly limited to 5 days.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Getason

Evidence for Use in Plaque Psoriasis

Research exploring the use of Getason (Betamethasone Dipropionate) for contexts related to moderate-to-severe plaque psoriasis primarily relies on short-term, randomized controlled trials (RCTs). These studies were used in research exploring how symptoms change over time, typically involving adults and adolescents. These trials generally compared the application of Getason against an inactive vehicle (a control cream or ointment without the active drug).

Studies monitored outcomes linked to inflammatory or irritative states, such as changes in the size, redness, and thickness of the psoriasis plaques. Findings described patterns observed in the studies related to changes in these specific physical signs of inflammation over short observation intervals, typically limited to between two and eight weeks.

Evidence for Use in Severe Eczema (Dermatitis)

The evidence base where Getason was evaluated for severe eczema (dermatitis) is rooted in short-term randomized controlled trials and comparative studies. This research was evaluated in studies focusing on episodes where symptoms become more noticeable, including adults, adolescents, and sometimes younger children (pediatric populations) experiencing an acute flare-up of their condition.

Studies explored outcomes related to physical discomfort, specifically monitoring for changes in pruritus (itching), scaling, and the intensity of inflammation. The trials generally reported measurements of symptom parameters in the observed populations during the defined time intervals, often lasting four weeks or less. This evidence contributes to the broader understanding of conditions involving periods of heightened symptoms.

What Remains Uncertain About Getason

The majority of high-quality research is designed to assess its use during short-term episodes of heightened symptom activity. This provides limited information for long-term outcomes regarding the use of Getason over many months or years. The existing evidence does not determine the overall long-term patterns of disease recurrence.

Research was evaluated in specific populations, most notably pediatric populations, but overall evidence is limited for long-term patterns in children compared to adults. Data for less common indications or special patient groups remain insufficient, meaning results apply only to the populations studied and cannot be easily generalized.

Key Studies & References

  1. Betamethasone Dipropionate Topical Cream, U.S. Food and Drug Administration (FDA) Prescribing Information (DailyMed)

Frequently Asked Questions (FAQ)

Common questions about Getason (FAQ)


Q: Can Getason be used for pain relief?

Official documents state the primary purpose of Getason is for its anti-inflammatory and anti-itching actions, which are intended to relieve symptoms of certain skin conditions. The official product label does not include generalized pain relief as an indicated use.


Q: Is Getason the same as other medications ending in '-sone'?

Getason belongs to the general drug class known as corticosteroids, many of which have names that end in '-sone.' Official descriptions classify Getason as a high-potency, synthetic adrenocorticosteroid analogue. While it is in the same class as many others, its specific chemical structure and topical use define its properties.


Q: What does 'systemic' mean when describing how Getason works?

When discussing topical medications like Getason, the term 'systemic' refers to the small amount of the drug that may be absorbed through the skin and enter the overall bloodstream. Once in the bloodstream, the substance is distributed throughout the body. Official warnings are in place to minimize this systemic exposure.


Q: Is feeling tired a common side effect of Getason?

Tiredness, or fatigue, is not specifically listed among the most common skin-related side effects in the topical product information. However, systemic absorption can lead to endocrine effects, which are sometimes associated with changes in energy levels.


Q: Can Getason affect sleep patterns?

Sleep pattern changes are not directly listed as a common reaction to the topical medication. Systemic absorption may cause endocrine and metabolic effects, which are general effects that relate to the body's overall function.


Q: Is Getason known to cause weight gain?

Weight gain is not listed as a frequent side effect in the topical product label. However, systemic absorption may lead to metabolic and endocrine effects, which are general concerns with corticosteroids.


Q: Does Getason interact with blood pressure medication?

The official product label does not specifically name blood pressure medications as an interacting class. However, because systemic absorption may occur, use is cautioned in patients who have conditions like fluid retention or high blood pressure.


Q: Can people with diabetes use Getason?

Official documents advise that the drug is labeled for use with caution in patients with diabetes. This caution is advised because systemic absorption of a corticosteroid may potentially interfere with blood sugar control or increase blood glucose levels.


Q: What does the package insert say about kidney or liver issues and Getason use?

Official documents indicate that liver failure may increase the risk of systemic side effects, such as HPA axis suppression, due to the body's decreased ability to break down the drug. The label does not contain specific warnings about pre-existing kidney conditions for topical use.


Q: How quickly does Getason usually start to work?

According to official patient information, the treated skin condition should generally show signs of improvement during the first two weeks of use. If there is no clinical improvement after two consecutive weeks, official guidelines state the diagnosis and treatment plan should be reassessed.


Q: Is Getason available over-the-counter?

No. Official regulatory documents classify Getason (Betamethasone Dipropionate) as an Rx only medication, meaning it requires a prescription from a healthcare provider.


Q: What happens if a dose of Getason is missed?

Patient instructions typically advise that if the missed dose is remembered soon after the scheduled time, it should be applied. If it is almost time for the next dose, the missed dose is usually skipped, and the regular schedule is continued.


Q: Can I take Getason while pregnant or breastfeeding?

Official regulatory documents classify the drug as Pregnancy Category C, which describes the general risk profile. For breastfeeding, official information indicates the drug can pass into breast milk.


Q: Is Getason known to interact with herbal supplements?

The official label advises patients to share their complete list of medicines and supplements, including over-the-counter products and herbal supplements, with their healthcare provider. This is to ensure all potential interactions and cumulative effects are considered.


Q: What are the known major drug interactions for Getason?

The primary interaction listed in the regulatory label is the additive systemic effect that occurs when Getason is used alongside other corticosteroid-containing products, whether topical or systemic. This additive effect can increase the risk of systemic side effects.


Q: Is there a link between Getason and mood changes?

Mood and behavior changes are not listed among the most common adverse reactions for the topical drug. However, mood changes have been documented with systemic corticosteroids and remain a possibility due to the potential for systemic absorption.


Q: Does Getason affect the immune system?

Yes, Getason is a type of corticosteroid, and these drugs are used for their anti-inflammatory and/or immunosuppressive effects. This action is the basis of its therapeutic use in certain inflammatory skin conditions.


Q: How long does Getason stay in your system after the last dose?

The small amount of drug that is absorbed through the skin is processed primarily in the liver and then eliminated from the body by the kidneys. It is excreted mainly as inactive substances.


Q: Can taking Getason affect the results of lab tests?

Yes. Due to the potential for the drug to cause reversible HPA axis suppression, laboratory tests are sometimes used for evaluation. These tests can include the ACTH stimulation test, morning plasma cortisol, and urinary free-cortisol tests.


Q: What does the evidence say about Getason's effect on bone density?

While the official product label for the topical drug does not explicitly list bone density loss, systemic absorption of the corticosteroid class has been historically associated with the potential for osteoporosis. This potential association is typically a concern when corticosteroids are used systemically or over long durations.


Q: Are there different strengths of Getason available?

Yes. The active ingredient Betamethasone Dipropionate is available in different strengths depending on the specific preparation, such as a cream, ointment, or lotion.


Q: Why is it important to share a full list of medicines before starting Getason?

Patients are instructed to share a full list of medicines and supplements to ensure their healthcare provider can consider the total systemic exposure to corticosteroids. This is crucial for monitoring the risk of potential systemic side effects.


Q: Is Getason a controlled substance?

No. Getason (Betamethasone Dipropionate) is classified as a dermatological corticosteroid and is not listed as a controlled substance under the main regulatory classification systems.


Q: Does Getason have any known contraindications related to heart conditions?

A specific contraindication for heart conditions is not listed in the topical drug's label. However, corticosteroids are generally advised for use with caution in patients with pre-existing conditions like fluid retention, hypertension, or congestive heart failure.


Q: What information is publicly available about how Getason was studied in clinical trials?

Publicly available regulatory information includes summaries of randomized controlled trials (RCTs). These studies were used to evaluate its use in conditions like plaque psoriasis and eczema, often comparing the drug to an inactive control substance.


Q: What are the initial signs that Getason is starting to work as intended?

As an anti-inflammatory and anti-itching agent, the initial signs of efficacy monitored in clinical studies included a reduction in the size, redness, thickness, and pruritus (itching) of the affected skin areas.

How should Getason be stored and disposed of?

How to Store and Dispose of Getason (Betamethasone Dipropionate)

The official storage conditions for Getason topical formulations are mandated to maintain the stability of the corticosteroid, while disposal follows pharmaceutical waste guidelines.

Official Storage Requirements

Item Regulatory Requirement
Temperature Range Store at Controlled Room Temperature, between 20°C to 25°C (68°F to 77°F).
Environmental Rules Protect the product from freezing and excessive heat. Keep away from moisture.
Container Rules Keep the container tightly closed and store the medicine in its original packaging.
Child Safety The medicine must be kept out of the sight and reach of children.

Disposal Instructions

Disposal of unused or expired Getason should be carried out through an authorized drug take-back program. If no such program is available, the product may be mixed with an undesirable substance, sealed in a bag, and then placed in the household trash, as specified by official waste protocols. The product is not required to be flushed down a sink or toilet.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Getason found in:

A-Z Index: